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·. Summary: This paper summarizes the practical experience gained in the Federal Republic of Germany in
connection with the development and implementation of a national reference System.
The National Reference System is set forth in:
1. the New Calibration Act 1986 (Neufassung des Eichgesetzes vom 22. Februar 1985. Bundesgesetzblatt
1985, Teil 1,410-422);
2. the New Weights and Measures Regulations 1988 (Eichordnung vom 12. August 1988. Bundesgesetzblatt
;
 1988, Teil I, 1657-1674),
3. the Guidelines of the Federal Medical Association (1988) for Quality Assurance in Medical Laboratories
(Richtlinien der Bundesärztekammer zur Qualitätssicherung in medizinischen Laboratorien vom 16. Januar
und 16. Oktober 1987. Deutsches Ärzteblatt 85 (11) (1988), A-699-A-712).
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It could be demonstrated that these differences are of
diagnostic and therapeutic relevance, because they can
lead to sizeable percentages of false classifications of
analytical results from patients. Hence the question
arose of what could be done to correct this Situation,
which was unacceptable for both patient care and
clinical research.
Where technically possible, the solution is to use only
analytical methods that yield results which are good
approximations of the "true value." By definition, the
best approximations of the true value are obtained
with Definitive Methods, and for the practical prob-
lems associated with control specimens, with Refer-
ence Methods. These facts served äs the basis for
development of a New Concept for quality control of
clinical laboratory fmdings.
New Concept
In the New Concept, the principle underlying the basic
Programme (tab. 1) was retained. However, the fol-
lowing changes were made (3, 5):
1. Accuracy control is now performed by comparison
of the analytical results with method-independent
reference method values. These reference method
values have replaced method-dependent assigned
values.
2. The maximum allowable deviations from the ref-
erence method values are specified with reference
to the medical requirements.
3. The maximum allowable imprecision for precision
control is specified in an analogous manner.
4. The decision limits for the interlaboratory surveys
are specified according to considerations analo-
gous to those for accuracy control.
For Implementation of the New Concept the follow-
ing were necessary:
1. Reference methods
2. Specification of the medical requirements
The reference methods are discussed later in this sym-
posium by experts on this subject.
The medical requirements have been formulated äs
follows.
The maximum allowable imprecision and the maxi-
mum allowable inaccuracy of the analyses should be
selected in such a way that the resulungproportion of.
incorrect classifications in the medical assessment of
analytical results is äs small äs possible.
Tab. l. Basic prograrame acc. to the Guidelines (3)
1. Internal qual i ty control
a. Control of precision
at the most frequent decision limit, by analysing samples
of the same control specimen in every ruri of analyses.
b. Control of accuracy
over the whole clinically relevant ränge of measurement,
by analysing an accuracy control specimen in every 4th
run of analyses; the control specimen is selected from a
relatively large number of difterent control specimens
kept on band.
2. External quality control
in the form of short-term interlaboratory surveys, using two
control specimens with different concentratioris.
In the medical assessment of analytical results the
percentage of false classifications resuiting from im-
precision and inaccuracy is to be kept äs small äs
possible.
An estimate must be made of the percentage of false
classifications to be expected.
This estimate is based oii the specifications for effec-
tive quality control of the analytical procedure.
For the different types of medical assessment — trans-
verse assessment (that is, comparison with a reference
interval, a decision limit or a therapeutic ränge) and
longitudinal assessment — a set of rules was devel-
oped for specifying the medical requirements.
These medical requirements can be met if routine
methods are used that are of proven reliability; soihe
comparisons of reference method values and assigned
values obtained with roütiöe methods are provided
äs documentation of reliability (tab. 2).
An unsohed problem is the vial-to-vial variability seen
with all lyophilized control speciinens, which can vary
markedly for different quantities. This vial-to-vial
variability must be assessed very carefully in the qual-
ity control of the production of control materials, and
must be taken into account in the protocol for detef-»
mining reference method values,
If control materials are used for calibration of analyt-
ical methods, considerable uncertainties -can be ex-
pected (even if the reference method value for the
analyte to be measured is used), because the mea-
surement signal can contain sizeable ünspecific com-
ponents from the matrix that do not come from the
analyte.
«.7
Vial-to-vial variability
In the course of our detemiinations of reference
method values in cöntf öl specimens we have had some
very surprising results. . *
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 29,1991 / No. 4
Stamm: Refercnce materials 249
Tab. 2. Comparison of reference method values and assigned values in lyophilized control specimen reg. No. 52600.
Quantity
(Unil)
S-calcium
(mval/1)
S-chloridc
(mval/1)
S-cholesterol
(mg/dl)
S-glucose
(mg/dl)
S-uric acid
(mg/dl)
S-potassium
(mval/1)
S-creatinine
(mg/dl)
S-magnesium
(mval/1)
S-sodium
(mval/l)
S-total protein
(g/dl)
S-total glycerol
for triacylglycerols
(mg/dl)
Reference
method value
4.43
101.3
123.85
93.35
5.485
4.38
1.395
1.811
143.8
5.895
11.52
Assigned value
Absolute
4.45
4.35
100
120
95.5
91.5
5.3
5.5
4.35
1.4
1.5
1.825
143.5
5.95
5.8
10.8
11.3
Fraction of
reference
method value
1.005
0.982
0.987
0.969
1.023
0.980
0.966
1.003
0.993
1.004
1.075
1.008
0.998
1.009
0.984
0.938
0.981
Method
Atomic absorption
Flame emission with lithium-guidelinc
Coulometric
Cholesterol oxidase /?-aminophenazone reaction
Hexokinase reaction
Glucose-dehydrogenase reaction
Uricase/aldehyde-dehydrogenase reaction
Enzymatic colour test
Flame emission with lithium-guideline
Enzymatic /?-aminophenazone reaction
Jaffe reaction, kinetic
Atomic absorption
Flame emission with lithium-guideline
Biuret method withoitt consideration of sample blank
with consideration of sample blank
Enzymatic after KOH saponification
Enzymatic, /?-aminophenazone reaction
For example, three reference laboratories determined
serum glucose with the hexokinase/glucose-6-phos-
phate dehydrogenase procedure, a National Glucose
Reference Method (6) established by the CDC, At-
lanta, USA in 1976. Each laboratory made 9 deter-
minations for each of 10 vials, and each laboratory
followed the protocol very carefully. Even the results
from a single laboratory (tab. 3) are surprising. Thus,
1. the mean values for the vials ränge from 103.05 to
106.84 mg/dl;
Tab. 3. Vial-to-vial variability
S-glucose (mg/dl): 9 analyses per vial with National
Reference Method, USA.
Vial
No.
1
2
3
4
5
6
7
8
9
10
Mean
(mg/dl)
103.05
104.90
105.43
103.79
105.35
106.54
106.32
106.84
105.42
106.10
CVA
(%)
0.73
0.96
0.88
0.95
0.86
0.86
0.55
0.82
0.62
0.69
2. analytical imprecision, expressed äs the coefficient
of Variation, is quite different for the different vials,
ranging from 0.55 to 0.96%.
These results were a compelling argument for us to
undertake a systematic study of the vial-to-vial vari-
ability of the reference method values in at least two
lots of control specimens, and the possible causes of
this variability. The results of these investigations were
then to serve äs the basis for an experimental design
to determine reference method values that would be
representative of an entire lot of a control specimen.
As possible causes of vial-to-vial variability, we looked
at the variability in the amount of material put into
each vial and at changes in the quantities dependent
on the time of filling and the position in the lyophilizer
(tab.4).
Tab. 4. Factors studied
äs possible causes of vial-to-vial variability, and suitable
quantities (in brackets).
1. Variability in the amount filled [S-sodium]
2. Change in quantity to be measured [S-glucose, S-bilirubin,
S-creatine kinase, S-aspartate aminotransferase (S-glutamate
oxaloacetate transaminase)] related to
2.1 Time of filling
2.2 Position in lyophilizer
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Quantities suitable for assessment of these effects are
shown in square brackets.
As the sampling plan shows (tab. 5), 6 vials each were
selected from 36 locations and clusters of 20 vials
each from 2 locations.
The protocol for analysis can only be outlined here
(tab. 6).
The results were evaluated with respect to both the
order of the analysis numbers and the order of the
sequence numbers, i. e. of time of filling and position
in the lyophilizer (tab. 7).
The following is a summary of the results.
1. There is a vial-to-vial variability which is different
for different analytes and which cannot be ex-
plained in terms of imprecision of measurement.
Tab. 5. Sampling plan.
J. 36 locations, 6 vials each = 216 vials
2. 2 locations, a cluster of 20 vials each = 40 vials
Associated with each sample and cluster is
— a specific filling time
— a specific position in the lyophilizer.
Each vial has
— a sequence nwnber (reflecting order of sampling)
— an analysis number (assigned at random and indicating order
of analysis).
2. For a given quantity this vial-to-vial variability is
independent of filling time and position in the
lyophilizer.
3. Therefore two clusters of 20 vials each yield the
same Information on vial-to7yial variability.
Table 8 shows the extent of the vial-to-vial variability
for 6 lots of specimens; 4 of these are control speci-
mens and 2 are very commonly used calibration spec-
imens from highly regarded manufacturers, but pur-
chased from a retail supplier, not directly from the
manufacturer.
After a look at these figures, the question arises of
the ränge of mean values that can be expected, ex-
pressed äs a percentage of the location parameter, for
each of the vial-to-vial variabilities found (tab. 9).
We then estimated the chances that a participant in
an interlaboratory survey would not get a certifieate
for a given quantity because of vial-to-vial variability.
We made our estimate, assuming the inaximum allow-
able imprecision äs specified after consideration of
the inedical requirements.
As a rule, the figure is no more than 0.3%. A publl·
cation on the model used and some realistic estimates
is in preparation.
Tab. 6. Protocol for analysis.
Analyses are performed in the order of the analysis
numbers.
This protocol excludes:
1. Errors occurring during reconstitution
2. Bacterial or other contamination
3. Changes before or during the analysis
5 analyses per vial
Calculation of mean and Standard deviation for each via!
Precision control with pools of 5 vials of lyophilized material;
S-sodium and S-glucose with additional liquid control material
Tab. 7. Evaluation of the analytical results.
The characteristics listed below were examined.
1. In the order of analysis
1.1 Vial means
l .2 Standard deviation for each vial
l .3 Analysis of outliers
2. In the order of filling
2.1 Distribution of vial means
2.1.1 in relation to position and filling time
2.1.2 in relation to filling time
2.1.3 in relation to position
2.1.4 for the clusters
2.1.5 for all samples
2.1.6 and comparison with clusters
Problems asspciated with the use of calibra-
tion specimens
Two types of problems arise.
1. Influence of vial-to-vial variability
Let us assume that a completely specific analytical
method is used. Even then, äs a result of the vial-
to-vial variability that we found in calibration spec-
imens from highly regarded manufacturers, and
depending on the size of the lot, the ränge of
concentrations around the vial mean can vary. In
a lot of 100000 vials, for example, serum glucose
values can be expected to have a ränge of 9%. · ·
2. Effect of the matrix on the "total measurement
Signal"
The matrix component of the measurement signal
(fig. 1) can have an additive effect, yielding a result
greäter than the "true value", or quench phenom-
ena or cross reactions can result in a signal less
than the "true value." In other words, if an un-
specific analytical method is used, the measurement
is inexact; in addition, the measured property is
not characterized unambiguously.
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Tab. 8. Coefficients of Variation for the vial means (vial-to-vial variability in %).
Material Analyte
Sodium Glucose Bilirubin Creatine
kinase
Aspartate aminotransferase
(Glutamale oxaloacetate
transaminase)
Control specimen
1 0.64
2 1.298
3 0.73
4 0.83
Calibration specimen
A 0.96
B 0.82
2.23
1.024
0.68
0.975
1.22
0.885
1.18
2.47
0.92
0.78
0.92
1.11
1.83
3.9
4.77
3.17
2.36
1.62
2.41
1.419
2.07
1.70
1.10
1.30
Tab. 9. Estimate of the ränge of the vial means
based on the vial-to-vial (vtv) variability for lots of
different sizes.
S-glucose
Location parameter 125.0 mg/dl
svtv 1.2825 mg/dl
CV™ 1.026 %
95% ränge 122.486-127.514 mg/dl
(±2.01%)
where
Range for
100 vials
1 000 vials
40 000 vials
80 000 vials
100000 vials
121.78-128.22
120.84-129.16
119.64-130.36
119.37-130.57
119.40-130.60
( + 2.57%)
(+3.32%)
(±4.29%)
(+4.45%)
(+4.48%)
Fräctionoftrue
Concentration value Signal
Reference method
Assigned value of
Routine method 1
Routine method 2
Routine method 3
Routine method 4
1.0
0.9
1.0
1.2
1-3
Fig. l. Components of the signal in a measuring procedure.
D signal fraction resulting from the value of true con-
centration (n) äs influenced by Signals due to unspecific
constituents (m)
Consequently, if the reference method value is used
in calibration, the following errors result:
TV
Total Signal
Signal corresponding to true value
Part of signal from unspecific com-
ponents in the matrix (different
from lot to lot)
CRMV cai
x A,
cal
•total specimen
where
CRMV
Example:
Concentration corresponding to
reference method value
Concentration measured in the
specimen analysed, dependent on
calibrator and analytical method
Motal — ± A•matrix
If Amatrix cal — 0.1 X ATV cab
then cp is roughly 10% too low or 10% too
high.
Awareness of these problems and of the extent to
which the analytical results can deviate from the ref-
erence method value should be enough to prevent
critical clinical chemists from using calibration spec-
imens for unspecific analytical methods.
The cholesterpl story, which Gerald Cooper teils us
about elsewhere in this issue (7), illustrates well how
precise and accurate analytical results in clinical chem-
istry must be if they are to serve äs the basis for valid
clinical laboratory findings, leading to responsible
medical action.
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